FDA approves Merck’s Noxafil (posaconazole) injection (18 mg/mL) for intravenous use

17-03-2014 Business Wire HealthComments (0)

BiotechnologyMerck & CoNoxafilPharmaceuticalUSA

Merck today announced that the US Food and Drug Administration has approved Noxafil (posaconazole) injection (18 mg/ mL), a new formulation of Noxafil for intravenous use.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top